Key players in major and bipolar depression-A retrospective analysis of in vivo imaging studies

Behavioural Brain Research

Volumn 232, Issue 2, 2012, Pages 358-390

  Nikolaus, Susanne ^a   Hautzel, Hubertus ^a   Heinzel, Alexander ^a   Müller, Hans Wilhelm ^a  

^a UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

Author keywords

Anxiety disorder; Bipolar depression; Major depressive disorder; Mania; PET; Remission; SPECT

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; ACETYLCHOLINE; DOPAMINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; HISTAMINE H1 RECEPTOR; MONOAMINE; NORADRENALIN; SEROTONIN 1A RECEPTOR; SEROTONIN 2A RECEPTOR; SEROTONIN RECEPTOR;

ADULT; AMYGDALOID NUCLEUS; ANXIETY DISORDER; ATTENTION DEFICIT DISORDER; BIPOLAR DEPRESSION; CEREBELLUM; CINGULATE GYRUS; CONTROLLED STUDY; CORPUS STRIATUM; DISEASE DURATION; FEMALE; FRONTAL CORTEX; HIPPOCAMPUS; HUMAN; IN VIVO STUDY; INSULA; LOCUS CERULEUS; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MANIA; MESENCEPHALON; NEOSTRIATUM; OCCIPITAL CORTEX; PARAHIPPOCAMPAL GYRUS; PARIETAL CORTEX; PONS ANGLE; POSITRON EMISSION TOMOGRAPHY; PREVALENCE; PRIORITY JOURNAL; RECEPTOR BINDING; REMISSION; RETROSPECTIVE STUDY; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SUBSTANTIA NIGRA; SYNAPSE; TEMPORAL CORTEX; THALAMUS;

BIPOLAR DISORDER; BRAIN; DEPRESSIVE DISORDER, MAJOR; HUMANS; NEURAL PATHWAYS; NEUROIMAGING; RETROSPECTIVE STUDIES; SEROTONIN; SYNAPTIC TRANSMISSION;

EID: 84861667176     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2012.03.021     Document Type: Review

References (200)

1. Lépine J.P., Briley M. The increasing burden of depression. Neuropsychiatr Dis Treat 2011, 7(Suppl. 1):3-7.
2. Kennedy S.H. Core symptoms of major depressive disorder: relevance to diagnosis and treatment. Dialogues Clin Neurosci 2008, 10:271-277.
3. Guelfi J.D. Classification of mood disorders in adults. Encephale 1995, 5:21-29.
4. Benazzi F. Various forms of depression. Dialogues Clin Neurosci 2006, 8:151-161.
5. Cassidy F., Yatham L.N., Berk M., Grof P. Pure and mixed manic subtypes: a review of diagnostic classification and validation. Bipolar Disord 2008, 10:131-143.
6. Piver A., Yatham L.N., Lam R.W. Bipolar spectrum disorders. New perspectives. Can Fam Physician 2002, 48:896-904.
7. Angst J., Gamma A., Benazzi F., Ajdacic V., Eich D., Rossler W. Toward a re-definition of subthreshold bipolarity: epidemiology and proposed criteria for bipolar-II, minor bipolar disorders and hypomania. J Affect Disord 2003, 73:133-146.
8. Krüger S., Prager P. Bipolar disorders: the disease of extreme emotions. MMW Fortschr Med 2007, 149(Suppl. 2):56-59.
9. Colom F., Vieta E. Sudden glory revisited: cognitive contents of hypomania. Psychother Psychosom 2007, 76:278-288.
10. Di Giovanni G., Di Matteo V., Pierucci M., Benigno A., Esposito E. Central serotonin2C receptor: from physiology to pathology. Curr Top Med Chem 2006, 6:1909-1925.
11. Werner F.M., Coveñas R. Classical neurotransmitters and neuropeptides involved in major depression: a review. Int J Neurosci 2010, 120:455-470.
12. Willner P. Dopamine and depression: a review of recent evidence. I. Empirical studies. Brain Res 1983, 287:211-224.
13. Liu X., Hairston J., Schrier M., Fan J. Common and distinct networks underlying reward valence and processing stages: a meta-analysis of functional neuroimaging studies. Neurosci Biobehav Rev 2011, 35:1219-1236.
14. Goddard A.W., Ball S.G., Martinez J., Robinson M.J., Yang C.R., Russell J.M., et al. Current perspectives of the roles of the central norepinephrine system in anxiety and depression. Depress Anxiety 2010, 27:339-350.
15. Racagni G., Popoli M. The pharmacological properties of antidepressants. Int Clin Psychopharmacol 2010, 25:117-131.
16. Ruhè H.G., Mason N.S., Schene A.H. Mood is directly related to serotonin, norepinephrine and dopamine levels in humans: a meta-analysis of monoamine depletion studies. Mol Psychiatry 2007, 12:331-359.
17. Hale M.W., Lowry C.A. Functional topography of midbrain and pontine serotonergic systems: implications for synaptic regulation of serotonergic circuits. Psychopharmacology (Berl) 2011, 213:243-264.
18. Haenisch B., Bönisch H. Depression and antidepressants: insights from knockout of dopamine, serotonin or noradrenaline re-uptake transporters. Pharmacol Ther 2011, 129:352-368.
19. Mineur Y.S., Picciotto M.R. Nicotine receptors and depression: revisiting and revising the cholinergic hypothesis. Trends Pharmacol Sci 2010, 31:580-586.
20. Scarr E. Muscarinic receptors in psychiatric disorders - can we mimic 'health'?. Neurosignals 2009, 17:298-310.
21. Mitchell N.D., Baker G.B. An update on the role of glutamate in the pathophysiology of depression. Acta Psychiatr Scand 2010, 122:192-210.
22. Yanai K., Tashiro M. The physiological and pathophysiological roles of neuronal histamine: an insight from human positron emission tomography studies. Pharmacol Ther 2007, 113:1-15.
23. Croarkin P.E., Levinson A.J., Daskalakis Z.J. Evidence for GABAergic inhibitory deficits in major depressive disorder. Neurosci Biobehav Rev 2011, 35:818-825.
24. Herman J.P., Seroogy K. Hypothalamic-pituitary-adrenal axis, glucocorticoids, and neurologic disease. Neurol Clin 2006, 24:461-481.
25. Birkhäuser M. Depression, menopause and estrogens: is there a correlation?. Maturitas 2002, 41(Suppl. 1):S3-S8.
26. Larisch R., Kley K., Nikolaus S., Sitte W., Franz M., Hautzel H., et al. Depression and anxiety in different thyroid function states. Horm Metab Res 2004, 36:650-653.
27. Rajewska J., Rybakowski J.K. Depression in premenopausal women: gonadal hormones and serotonergic system assessed by d-fenfluramine challenge test. Prog Neuropsychopharmacol Biol Psychiatry 2003, 27:705-709.
28. Lohoff F.W. Overview of the genetics of major depressive disorder. Curr Psychiatry Rep 2010, 12:539-546.
29. Serretti A., Mandelli L. The genetics of bipolar disorder: genome 'hot regions,' genes, new potential candidates and future directions. Mol Psychiatry 2008, 13:742-771.
30. Nikolaus S., Antke C., Kley K., Poeppel T.D., Hautzel H., Schmidt D., et al. Investigating the dopaminergic synapse in vivo. I. Molecular imaging studies in humans. Rev Neurosci 2007, 18:439-472.
31. Nikolaus S., Antke C., Müller H.W. In vivo imaging of synaptic function in the central nervous system. II. Mental and affective disorders. Behav Brain Res 2009, 204:32-66.
32. 11C]5-hydroxytryptophan in major depression: a positron emission tomography study on patients and healthy volunteers. Acta Psychiatr Scand 1991, 83:449-455.
33. 11C]dopa in brains of healthy volunteers and patients with major depression. Clin Neuropharmacol 1992, 15(Suppl. 1 (Pt A)):235-236.
34. Agren H., Reibring L. PET studies of presynaptic monoamine metabolism in depressed patients and healthy volunteers. Pharmacopsychiatry 1994, 27:2-6.
35. Amsterdam J.D., Newberg A.B. A preliminary study of dopamine transporter binding in bipolar and unipolar depressed patients and healthy controls. Neuropsychobiology 2007, 55:167-170.
36. Anand A., Verhoeff P., Seneca N., Zoghbi S.S., Seibyl J.P., Charney D.S., et al. Brain SPECT imaging of amphetamine-induced dopamine release in euthymic bipolar disorder patients. Am J Psychiatry 2000, 157:1108-1114.
37. 99mTc-TRODAT-1 SPECT study. J Affect Disord 2005, 89:115-123.
38. 18F]-setoperone during depressive illness and antidepressant treatment with clomipramine. Biol Psychiatry 1999, 45:180-186.
39. 11C]WAY-100635. Mol Psychiatry 2004, 9:386-392.
40. Bhagwagar Z., Hinz R., Taylor M., Fancy S., Cowen P., Grasby P. Increased 5-HT(2A) receptor binding in euthymic, medication-free patients recovered from depression: a positron emission study with [(11)C]MDL 100,907. Am J Psychiatry 2006, 163:1580-1587.
41. 11C]DASB. Am J Psychiatry 2007, 164:1858-1865.
42. Biver F., Wikler D., Lotstra F., Damhaut P., Goldman S., Mendlewicz J. Serotonin 5-HT2 receptor imaging in major depression: focal changes in orbito-insular cortex. Br J Psychiatry 1997, 171:444-448.
43. 11C]DASB. Mov Disord 2008, 23:1776-1780.
44. 99mTc]TRODAT-1 SPECT imaging. Am J Psychiatry 2003, 160:1836-1841.
45. Busto U.E., Redden L., Mayberg H., Kapur S., Houle S., Zawertailo L.A. Dopaminergic activity in depressed smokers: a positron emission tomography study. Synapse 2009, 63:681-689.
46. 11C]DASB and positron emission tomography. Biol Psychiatry 2006, 60:207-217.
47. Cannon D.M., Carson R.E., Nugent A.C., Eckelman W.C., Kiesewetter D.O., Williams J., et al. Reduced muscarinic type 2 receptor binding in subjects with bipolar disorder. Arch Gen Psychiatry 2006, 63:741-747.
48. 11C]DASB; comparison with bipolar disorder. Biol Psychiatry 2007, 62:870-877.
49. 11C]NNC-112. Neuropsychopharmacology 2009, 34:1277-1287.
50. 123I-ADAM SPECT study. Psychopharmacology (Berl) 2006, 189:145-153.
51. Chang T.T., Yeh T.L., Chiu N.T., Chen P.S., Huang H.Y., Yang Y.K., et al. Higher striatal dopamine transporters in euthymic patients with bipolar disorder: a SPECT study with [Tc] TRODAT-1. Bipolar Disord 2010, 12:102-106.
52. Chou Y.H., Wang S.J., Lin C.L., Mao W.C., Lee S.M., Liao M.H. Decreased brain serotonin transporter binding in the euthymic state of bipolar I but not bipolar II disorder: a SPECT study. Bipolar Disord 2010, 12:312-318.
53. Dahlstrom M., Ahonen A., Ebeling H., Torniainen P., Heikkila J., Moilanen I. Elevated hypothalamic/midbrain serotonin (monoamine) transporter availability in depressive drug-naive children and adolescents. Mol Psychiatry 2000, 5:514-522.
54. D'haenen H., Bossuyt A., Mertens J., Bossuyt-Piron C., Gijsemans M., Kaufman L. SPECT imaging of serotonin2 receptors in depression. Psychiatry Res 1992, 45:227-237.
55. D'haenen H.A., Bossuyt A. Dopamine D2 receptors in depression measured with single photon emission computed tomography. Biol Psychiatry 1994, 35:128-132.
56. 11C]SCH 23,390 in patients with major depression with anger attacks. Depress Anxiety 2006, 23:175-177.
57. Drevets W.C., Frank E., Price J.C., Kupfer D.J., Holt D., Greer P.J., et al. PET imaging of serotonin 1A receptor binding in depression. Biol Psychiatry 1999, 46:1375-1387.
58. Drevets W.C., Frank E., Price J.C., Kupfer D.J., Greer P.J., Mathis C. Serotonin type-1A receptor imaging in depression. Nucl Med Biol 2000, 27:499-507.
59. Drevets W.C., Thase M.E., Moses-Kolko E.L., Price J., Frank E., Kupfer D.J., et al. Serotonin-1A receptor imaging in recurrent depression: replication and literature review. Nucl Med Biol 2007, 34:865-877.
60. Ebert D., Feistel H., Kaschka W., Barocka A., Pirner A. Single photon emission computerized tomography assessment of cerebral dopamine D2 receptor blockade in depression before and after sleep deprivation - preliminary results. Biol Psychiatry 1994, 35:880-885.
61. Ebert D., Feistel H., Loew T., Pirner A. Dopamine and depression - striatal dopamine D2 receptor SPECT before and after antidepressant therapy. Psychopharmacology (Berl) 1996, 126:91-94.
62. Felicio A.C., Moriyama T.S., Godeiro-Junior C., Shih M.C., Hoexter M.Q., Borges V., et al. Higher dopamine transporter density in Parkinson's disease patients with depression. Psychopharmacology (Berl) 2010, 211:27-31.
63. Frey B.N., Skelin I., Sakai Y., Nishikawa M., Diksic M. Gender differences in alpha-[(11)C]MTrp brain trapping, an index of serotonin synthesis, in medication-free individuals with major depressive disorder: a positron emission tomography study. Psychiatry Res 2010, 183:157-166.
64. 11C]DASB-PET in depressed and non-depressed patients infected with HIV. Neuroimage 2010, 49:2588-2595.
65. 1A receptor binding in temporal lobe epilepsy patients with and without major depression. Biol Psychiatry 2007, 62:1258-1264.
66. 123I]-ADAM. J Neural Transm 2006, 113:659-670.
67. 11C]raclopride PET. Psychopharmacology (Berl) 2008, 197:581-590.
68. 11C]WAY-100635. Int J Neuropsychopharmacol 2008, 11:465-476.
69. Hsieh P.C., Lee I.H., Yeh T.L., Chen K.C., Huang H.C., Chen P.S., et al. Distribution volume ratio of serotonin and dopamine transporters in euthymic patients with a history of major depression - a dual-isotope SPECT study. Psychiatry Res 2010, 184:157-161.
70. 11C](+)McN5652. Biol Psychiatry 2002, 51:715-722.
71. Joensuu M., Tolmunen T., Saarinen P.I., Tiihonen J., Kuikka J., Ahola P., et al. Reduced midbrain serotonin transporter availability in drug-naïve patients with depression measured by SERT-specific [(123)I] nor-beta-CIT SPECT imaging. Psychiatry Res 2007, 154:125-131.
72. Kano M., Fukudo S., Tashiro A., Utsumi A., Tamura D., Itoh M., et al. Decreased histamine H1 receptor binding in the brain of depressed patients. Eur J Neurosci 2004, 20:803-810.
73. 1A receptors in patients with major depressive disorder. Psychol Med 2010, 40:523-528.
74. 123I]IBZM SPECT. Psychiatry Res 1999, 90:91-101.
75. 123I]iomazenil SPECT. Biol Psychiatry 2003, 54:792-799.
76. Laasonen-Balk T., Kuikka J., Viinamakki H., Husso-Saastamoinen M., Lehtonen J., Tiihonen J. Striatal dopamine transporter density in major depression. Psychopharmacology (Berl) 1999, 144:282-285.
77. Larisch R., Klimke A., Mayoral F., Hamacher K., Herzog H.R., Vosberg H., et al. Disturbance of serotonin 5HT2 receptors in remitted patients suffering from hereditary depressive disorder. Nuklearmedizin 2001, 40:129-134.
78. 123I]nor-beta-CIT in atypical depression. Prog Neuropsychopharmacol Biol Psychiatry 2006, 30:1251-1255.
79. Lehto S.M., Kuikka J., Tolmunen T., Hintikka J., Viinamäkki H., Vanninen R., et al. Temporal cortex dopamine D2/3 receptor binding in major depression. Psychiatry Clin Neurosci 2008, 62:345-348.
80. Lehto S.M., Tolmunen T., Kuikka J., Valkonen-Korhonen M., Joensuu M., Saarinen P.I., et al. Midbrain serotonin and striatum dopamine transporter binding in double depression: a one-year follow-up study. Neurosci Lett 2008, 441:291-295.
81. Lundgren J.D., Amsterdam J., Newberg A., Allison K.C., Wintering N., Stunkard A.J. Differences in serotonin transporter binding affinity in patients with major depressive disorder and night eating syndrome. Eat Weight Disord 2009, 14:45-50.
82. 123I]-2 beta-carbomethoxy-3 beta-(4-iodophenyl)tropane and single photon emission computed tomography. Biol Psychiatry 1998, 44:1090-1098.
83. Martinot M., Bragulat V., Artiges E., Dollé F., Hinnen F., Jouvent R., et al. Decreased presynaptic dopamine function in the left caudate of depressed patients with affective flattening and psychomotor retardation. Am J Psychiatry 2001, 158:314-316.
84. Meltzer C.C., Price J.C., Mathis C.A., Greer P.J., Cantwell M.N., Houck P.R., et al. PET imaging of serotonin type 2A receptors in late-life neuropsychiatric disorders. Am J Psychiatry 1999, 156:1871-1878.
85. Messa C., Colombo C., Moresco R.M., Gobbo C., Galli L., Lucignani G., et al. 5-HT(2A) receptor binding is reduced in drug-naive and unchanged in SSRI-responder depressed patients compared to healthy controls: a PET study. Psychopharmacology (Berl) 2003, 167:72-78.
86. 18F]setoperone PET imaging study. Am J Psychiatry 1999, 156:1029-1034.
87. Meyer J.H., Kruger S., Wilson A.A., Christensen B.K., Goulding V.S., Schaffer A., et al. Lower dopamine transporter binding potential in striatum during depression. Neuroreport 2001, 12:4121-4125.
88. Meyer J.H., Kapur S., Eisfeld B., Brown G.M., Houle S., DaSilva J., et al. The effect of paroxetine on 5-HT(2A) receptors in depression: an [(18)F]setoperone PET imaging study. Am J Psychiatry 2001, 158:78-85.
89. Meyer J.H., Wilson A.A., Ginovart N., Goulding V., Hussey D., Hood K., et al. Occupancy of serotonin transporters by paroxetine and citalopram during treatment of depression: a [(11)C]DASB PET imaging study. Am J Psychiatry 2001, 158:1843-1849.
90. Meyer J.H., Houle S., Sagrati S., Carella A., Hussey D.F., Ginovart N., et al. Brain serotonin transporter binding potential measured with carbon 11-labeled DASB positron emission tomography: effects of major depressive episodes and severity of dysfunctional attitudes. Arch Gen Psychiatry 2004, 61:1271-1279.
91. 11C]DASB positron emission tomography study. Am J Psychiatry 2004, 161:826-835.
92. 11C]raclopride positron emission tomography study. Am J Psychiatry 2006, 163:1594-1602.
93. Miller J.M., Oquendo M.A., Ogden R.T., Mann J.J., Parsey R.V. Serotonin transporter binding as a possible predictor of one-year remission in major depressive disorder. J Psychiatr Res 2008, 42:1137-1144.
94. Miller J.M., Brennan K.G., Ogden T.R., Oquendo M.A., Sullivan G.M., Mann J.J., et al. Elevated serotonin 1A binding in remitted major depressive disorder: evidence for a trait biological abnormality. Neuropsychopharmacology 2009, 34:2275-2284.
95. Miller J.M., Kinnally E.L., Ogden R.T., Oquendo M.A., Mann J.J., Parsey R.V. Reported childhood abuse is associated with low serotonin transporter binding in vivo in major depressive disorder. Synapse 2009, 63:565-573.
96. 18F]altanserin positron emission tomography. Biol Psychiatry 2004, 55:217-224.
97. 11C]raclopride. J Affect Disord 2007, 101:113-122.
98. Murrough J.W., Henry S., Hu J., Gallezot J.D., Planeta-Wilson B., Neumaier J.F., et al. Reduced ventral striatal/ventral pallidal serotonin1B receptor binding potential in major depressive disorder. Psychopharmacology (Berl) 2011, 213:547-553.
99. 123I-ADAM binding to serotonin transporters in patients with major depression and healthy controls: a preliminary study. J Nucl Med 2005, 46:973-977.
100. Oquendo M.A., Hastings R.S., Huang Y.Y., Simpson N., Ogden R.T., Hu X.Z., et al. Brain serotonin transporter binding in depressed patients with bipolar disorder using positron emission tomography. Arch Gen Psychiatry 2007, 64:201-208.
101. Parsey R.V., Oquendo M.A., Zea-Ponce Y., Rodenhiser J., Kegeles L.S., Pratap M., et al. Dopamine D(2) receptor availability and amphetamine-induced dopamine release in unipolar depression. Biol Psychiatry 2001, 50:313-322.
102. Parsey R.V., Oquendo M.A., Ogden R.T., Olvet D.M., Simpson N., Huang Y.Y., et al. Altered serotonin 1A binding in major depression: a [carbonyl-C-11]WAY100635 positron emission tomography study. Biol Psychiatry 2006, 59:106-113.
103. Parsey R.V., Hastings R.S., Oquendo M.A., Huang Y.Y., Simpson N., Arcement J., et al. Lower serotonin transporter binding potential in the human brain during major depressive episodes. Am J Psychiatry 2006, 163:52-58.
104. 1A receptor binding potential during a major depressive episode predicts poor treatment response: preliminary data from a naturalistic study. Neuropsychopharmacology 2006, 31:1745-1749.
105. Pearlson G.D., Wong D.F., Tune L.E., Ross C.A., Chase G.A., Links J.M., et al. In vivo D2 dopamine receptor density in psychotic and nonpsychotic patients with bipolar disorder. Arch Gen Psychiatry 1995, 52:471-477.
106. 11C-DASB PET study. Neurobiol Dis 2010, 40:216-221.
107. 11C]DASB PET study. Mol Psychiatry 2008, 13:606-613.
108. 11C](+)McN5652 shows increased serotonin transporter availability in major depression. J Affect Disord 2004, 82:321-327.
109. Remy P., Doder M., Lees A., Turjanski N., Brooks D. Depression in Parkinson's disease: loss of dopamine and noradrenaline innervation in the limbic system. Brain 2005, 128:1314-1322.
110. 11C]methyl-l-tryptophan trapping as a measure of serotonin synthesis in medication-free patients with major depression. Arch Gen Psychiatry 2004, 61:556-563.
111. 123I]beta-CIT SPECT in major depressive disorder versus controls: effect of season and gender. Eur J Nucl Med Mol Imaging 2009, 36:841-849.
112. Saarinen P.I., Lehtonen J., Joensuu M., Tolmunen T., Ahola P., Vanninen R., et al. An outcome of psychodynamic psychotherapy: a case study of the change in serotonin transporter binding and the activation of the dream screen. Am J Psychother 2005, 59:61-73.
113. 11C]FLB 457. J Clin Psychiatry 2010, 71:793-799.
114. Sarchiapone M., Carli V., Camardese G., Cuomo C., Di Giuda D., Calcagni M.L., et al. Dopamine transporter binding in depressed patients with anhedonia. Psychiatry Res 2006, 147:243-248.
115. 11C]WAY-100635: effects of depression and antidepressant treatment. Arch Gen Psychiatry 2000, 57:174-180.
116. Sargent P.A., Rabiner E.A., Bhagwagar Z., Clark L., Cowen P., Goodwin G.M., et al. 5-HT(1A) receptor binding in euthymic bipolar patients using positron emission tomography with [carbonyl-(11)C]WAY-100635. J Affect Disord 2010, 123:77-80.
117. Shah P.J., Ogilvie A.D., Goodwin G.M., Ebmeier K.P. Clinical and psychometric correlates of dopamine D2 binding in depression. Psychol Med 1997, 27:1247-1256.
118. 18F]altanserin positron emission tomography. Neuropsychopharmacology 2004, 29:2235-2241.
119. 11C]Mirtazapine binding in depressed antidepressant nonresponders studied by PET neuroimaging. Psychopharmacology (Berl) 2009, 206:133-140.
120. Staley J.K., Sanacora G., Tamagnan G., Maciejewski P.K., Malison R.T., Berman R.M., et al. Sex differences in diencephalon serotonin transporter availability in major depression. Biol Psychiatry 2006, 59:40-47.
121. Suhara T., Nakayama K., Inoue O., Fukuda H., Shimizu M., Mori A., et al. D1 dopamine receptor binding in mood disorders measured by positron emission tomography. Psychopharmacology (Berl) 1992, 106:14-18.
122. Sullivan G.M., Ogden R.T., Oquendo M.A., Kumar J.S., Simpson N., Huang Y.Y., et al. Positron emission tomography quantification of serotonin-1A receptor binding in medication-free bipolar depression. Biol Psychiatry 2009, 66:223-230.
123. 1A PET receptor binding and depression in temporal lobe epilepsy. Epilepsia 2007, 48:1526-1530.
124. Tolmunen T., Joensuu M., Saarinen P.I., Mussalo H., Ahola P., Vanninen R., et al. Elevated midbrain serotonin transporter availability in mixed mania: a case report. BMC Psychiatry 2004, 4:27.
125. Viinamäkki H., Kuikka J., Tiihonen J., Lehtonen J. Change in monoamine transporter density related to clinical recovery: a case-control study. Nord J Psychiatry 1998, 52:39-44.
126. Wong D.F., Pearlson G.D., Tune L.E., Young L.T., Meltzer C.C., Dannals R.F., et al. Quantification of neuroreceptors in the living human brain: IV. Effect of aging and elevations of D2-like receptors in schizophrenia and bipolar illness. J Cereb Blood Flow Metab 1997, 17:331-342.
127. Yang Y.K., Yeh T.L., Yao W.J., Lee I.H., Chen P.S., Chiu N.T., et al. Greater availability of dopamine transporters in patients with major depression - a dual-isotope SPECT study. Psychiatry Res 2008, 162:230-235.
128. Yatham L.N., Liddle P.F., Shiah I.S., Scarrow G., Lam R.W., Adam M.J., et al. Brain serotonin2 receptors in major depression: a positron emission tomography study. Arch Gen Psychiatry 2000, 57:850-858.
129. Yatham L.N., Liddle P.F., Shiah I.S., Lam R.W., Ngan E., Scarrow G., et al. PET study of [(18)F]6-fluoro-l-dopa uptake in neuroleptic- and mood-stabilizer-naive first-episode nonpsychotic mania: effects of treatment with divalproex sodium. Am J Psychiatry 2002, 159:768-774.
130. Yatham L.N., Liddle P.F., Erez J., Kauer-Sant'Anna M., Lam R.W., Imperial M., et al. Brain serotonin-2 receptors in acute mania. Br J Psychiatry 2010, 196:47-51.
131. Moses-Kolko E.L., Wisner K.L., Price J.C., Berga S.L., Drevets W.C., Hanusa B.H., et al. Serotonin 1A receptor reductions in postpartum depression: a positron emission tomography study. Fertil Steril 2008, 89:685-692.
132. Neumeister A., Willeit M., Praschak-Rieder N., Asenbaum S., Stastny J., Hilger E., et al. Dopamine transporter availability in symptomatic depressed patients with seasonal affective disorder and healthy controls. Psychol Med 2001, 31:1467-1473.
133. 123I]-beta-CIT SPECT imaging shows reduced brain serotonin transporter availability in drug-free depressed patients with seasonal affective disorder. Biol Psychiatry 2000, 47:482-489.
134. Audenaert K., Van Laere K., Dumont F., Slegers G., Mertens J., van Heeringen C., et al. Decreased frontal serotonin 5-HT 2a receptor binding index in deliberate self-harm patients. Eur J Nucl Med 2001, 28:175-182.
135. Bah J., Lindström M., Westberg L., Mannerås L., Ryding E., Henningsson S., et al. Serotonin transporter gene polymorphisms: effect on serotonin transporter availability in the brain of suicide attempters. Psychiatry Res 2008, 162:221-229.
136. Meyer J.H., McMain S., Kennedy S.H., Korman L., Brown G.M., DaSilva J.N., et al. Dysfunctional attitudes and 5-HT2 receptors during depression and self-harm. Am J Psychiatry 2003, 160:90-99.
137. Ryding E., Ahnlide J.A., Lindström M., Rosén I., Träskman-Bendz L. Regional brain serotonin and dopamine transporter binding capacity in suicide attempters relate to impulsiveness and mental energy. Psychiatry Res 2006, 148:195-203.
138. van Heeringen C., Audenaert K., Van Laere K., Dumont F., Slegers G., Mertens J., et al. Prefrontal 5-HT2a receptor binding index, hopelessness and personality characteristics in attempted suicide. J Affect Disord 2003, 74:149-158.
139. Rendu F., Peoc'h K., Berlin I., Thomas D., Launay J.M. Smoking related diseases: the central role of monoamine oxidase. Int J Environ Res Public Health 2011, 8:136-147.
140. Best J., Nijhout H.F., Reed M. Serotonin synthesis, release and reuptake in terminals: a mathematical model. Theor Biol Med Model 2010, 7:34.
141. Kuhar M.J., Couceyro P.R., Lambert P.D. Catecholamines. Basic neurochemistry - molecular, cellular and medical aspects 1998, 243-261. Lippincott, Williams & Wilkins, Baltimore. 6th ed. G.J. Siegel, B.W. Agranoff, R.W. Albers, S.K. Fisher, M.D. Whaler (Eds.).
142. Miranda M., Sorkin A. Regulation of receptors and transporters by ubiquitination: new insights into surprisingly similar mechanisms. Mol Interv 2007, 7:157-167.
143. Steiner J.A., Carneiro A.M., Blakely R.D. Going with the flow: trafficking-dependent and -independent regulation of serotonin transport. Traffic 2008, 9:1393-1402.
144. Eriksen J., Jørgensen T.N., Gether U. Regulation of dopamine transporter function by protein-protein interactions: new discoveries and methodological challenges. J Neurochem 2010, 113:27-41.
145. Ferguson S.S. Evolving concepts in G protein-coupled receptor endocytosis: the role in receptor desensitization and signaling. Pharmacol Rev 2001, 53:1-24.
146. Elhwuegi A.S. Central monoamines and their role in major depression. Prog Neuropsychopharmacol Biol Psychiatry 2004, 28:435-451.
147. Leonhardt S., Gorospe E., Hoffman B.J., Teitler M. Molecular pharmacological differences in the interaction of serotonin with 5-hydroxytryptamine1C and 5-hydroxytryptamine2 receptors. Mol Pharmacol 1992, 42:328-335.
148. Egan C., Grinde E., Dupre A., Roth B.L., Hake M., Teitler M., et al. Agonist high and low affinity state ratios predict drug intrinsic activity and a revised ternary complex mechanism at serotonin 5-HT(2A) and 5-HT(2C) receptors. Synapse 2000, 35:144-150.
149. Seeman P., Weinshenker D., Quirion R., Srivastava L.K., Bhardwaj S.K., Grandy D.K., et al. Dopamine supersensitivity correlates with D2High states, implying many paths to psychosis. Proc Natl Acad Sci USA 2005, 10:3513-3518.
150. Blier P., de Montigny C. Current advances and trends in the treatment of depression. Trends Pharmacol Sci 1994, 15:220-226.
151. Riad M., Watkins K.C., Doucet E., Hamon M., Descarries L. Agonist-induced internalization of serotonin-1A receptors in the dorsal raphe nucleus (autoreceptors) but not hippocampus (heteroreceptors). J Neurosci 2001, 21:8378-8386.
152. Andrews P.W., Kornstein S.G., Halberstadt L.J., Gardner C.O., Neale M.C. Blue again: perturbational effects of antidepressants suggest monoaminergic homeostasis in major depression. Front Psychol 2011, 2:159.
153. 1B agonists. Synapse 1987, 1:3-9.
154. Alex K.D., Pehek E.A. Pharmacologic mechanisms of serotonergic regulation of dopamine neurotransmission. Pharmacol Ther 2007, 113:296-320.
155. Ferré S., Cortés R., Artigas F. Dopaminergic regulation of the serotonergic raphe-striatal pathway: microdialysis studies in freely moving rats. J Neurosci 1994, 14:4839-4846.
156. 3H]-serotonin from the rat substantia nigra. Naunyn Schmiedebergs Arch Pharmacol 1987, 335:502-507.
157. Son L.Z., Yanai K., Mobarakeh J.I., Kuramasu A., Li Z.Y., Sakurai E., et al. Histamine H1 receptor-mediated inhibition of potassium-evoked release of 5-hydroxytryptamine from mouse forebrains. Behav Brain Res 2001, 124:113-120.
158. Sergeeva O.A., Schulz D., Doreulee N., Ponomarenko A.A., Selbach O., Borsch E., et al. Deficits in cortico-striatal synaptic plasticity and behavioral habituation in rats with portacaval anastomosis. Neuroscience 2005, 134:1091-1098.
159. Eriksson K.S., Stevens D.R., Haas H.L. Serotonin excites tuberomammillary neurons by activation of Na(+)/Ca(2+)-exchange. Neuropharmacology 2001, 40:345-351.
160. Guiard B.P., El Mansari M., Blier P. Cross-talk between dopaminergic and noradrenergic systems in the rat ventral tegmental area, locus coeruleus, and dorsal hippocampus. Mol Pharmacol 2008, 74:1463-1475.
161. Kalsner S., Abdali S.A. Rate-independent inhibition by norepinephrine of 5-HT release from the somadendritic region of serotonergic neurons. Brain Res Bull 2001, 55:761-765.
162. Cedarbaum J.M., Aghajanian G.K. Catecholamine receptors on locus coeruleus neurons: pharmacological characterization. Eur J Pharmacol 1977, 44:375-385.
163. Suzuki M., Matsuda T., Asano S., Somboonthum P., Takuma K., Baba A. Increase of noradrenaline release in the hypothalamus of freely moving rat by postsynaptic 5-hydroxytryptamine1A receptor activation. Br J Pharmacol 1995, 115:703-711.
164. Done C.J., Sharp T. Evidence that 5-HT2 receptor activation decreases noradrenaline release in rat hippocampus in vivo. Br J Pharmacol 1992, 107:240-245.
165. Giorguieff M.F., Le Floch M.L. Presynaptic receptors of nicotinic and muscarinic types in the control of the spontaneous release of DA from striatal dopaminergic terminals in the rat. J Pharmacol Exp Ther 1990, 200:535-544.
166. Marchi M., Fontana G., Paudice P., Raiteri M. The activation of phosphatidylinositol turnover is not directly involved in the modulation of neurotransmitter release mediated by presynaptic muscarinic receptors. Neurochem Res 1988, 13:903-907.
167. Lehmann J., Langer S.Z. The striatal cholinergic interneuron: synaptic target of dopaminergic terminals?. Neuroscience 1983, 10(December (4)):1105-1120.
168. Rada P.V., Mark G.P., Hoebel B.G. In vivo modulation of acetylcholine in the nucleus accumbens of freely moving rats: I. Inhibition by serotonin. Brain Res 1993, 619:98-104.
169. Hirano H., Day J., Fibiger H.C. Serotonergic regulation of acetylcholine release in rat frontal cortex. J Neurochem 1995, 65:1139-1145.
170. Nikolaus S., Larisch R., Beu M., Vosberg H., Müller-Gärtner H.W. Diffuse cortical reduction of neuronal activity in unipolar major depression - a retrospective analysis of 337 patients and 321 controls. Nucl Med Commun 2000, 21:1119-1126.
171. Schildkraut J.J. The catecholamine hypothesis of affective disorders: a review of supporting evidence. Am J Psychiatry 1965, 1222:509-522.
172. Coppen A. The biochemistry of affective disorders. Br J Psychiatry 1967, 113:1237-1264.
173. Cao J.L., Covington H.E., Friedman A.K., Wilkinson M.B., Walsh J.J., Cooper D.C., et al. Mesolimbic dopamine neurons in the brain reward circuit mediate susceptibility to social defeat and antidepressant action. J Neurosci 2010, 30:16453-16458.
174. Heinzel A., Northoff G., Boeker H., Boesiger P., Grimm S. Emotional processing and executive function in major depressive disorder: dorsal prefrontal activity correlates with performance in the intra-extra dimensional set shift. Acta Neuropsychiatrica 2010, 22:269-279.
175. Piñeyro G., Blier P. Autoregulation of serotonin neurons: role in antidepressant drug action. Pharmacol Rev 1999, 51:533-591.
176. 18F]altanserin binding to 5HT2 receptors in man. Behav Brain Res 2003, 139:21-29.
177. 18F]altanserin. Neuroimage 2011, 58:905-911.
178. Quednow B.B., Treyer V., Hasler F., Dörig N., Wyss M.T., Burger C., et al. Assessment of serotonin release capacity in the human brain using dexfenfluramine challenge and [(18)F]altanserin positron emission tomography. Neuroimage 2012, 59:3922-3932.
179. 11C]raclopride displacement and PET. Neurology 1996, 46:1430-1436.
180. Pavese N., Evans A.H., Tai Y.F., Hotton G., Brooks D.J., Lees A.J., et al. Clinical correlates of levodopa-induced dopamine release in Parkinson disease: a PET study. Neurology 2006, 67:1612-1617.
181. Nikolaus S., Antke C., Müller H.W. In vivo imaging of synaptic function in the central nervous system. I. Movement disorders and dementia. Behav Brain Res 2009, 204:1-31.
182. Lewis A., Miller J.A., Lea R.A. Monoamine oxidase and tobacco dependence. Neurotoxicology 2007, 28:182-195.
183. Horton R.W. The neurochemistry of depression: evidence derived from studies of post-mortem brain tissue. Mol Aspects Med 1992, 13:191-203.
184. Applebaum J., Bersudsky Y., Klein E. Rapid tryptophan depletion as a treatment for acute mania: a double-blind, pilot-controlled study. Bipolar Disord 2007, 9:884-887.
185. Mundo E., Walker M., Cate T., Macciardi F., Kennedy J.L. The role of serotonin transporter protein gene in antidepressant-induced mania in bipolar disorder: preliminary findings. Arch Gen Psychiatry 2001, 58:539-544.
186. Murphy D.L., Brodie H.K., Goodwin F.K., Bunney W.E. Regular induction of hypomania by l-dopa in " bipolar" manic-depressive patients. Nature 1971, 229:135-136.
187. Jacobs D., Silverstone T. Dextroamphetamine-induced arousal in human subjects as a model for mania. Psychol Med 1986, 16:323-329.
188. Nikolaus S., Beu M., Antke C., Müller H.W. Cortical GABA, striatal dopamine and midbrain serotonin as the key players in compulsive and anxiety disorders - results from in vivo imaging studies. Rev Neurosci 2010, 21:119-139.
189. Bush G. Cingulate, frontal, and parietal cortical dysfunction in attention-deficit/hyperactivity disorder. Biol Psychiatry 2011, 69:1160-1167.
190. Walter M., Henning A., Grimm S., Schulte R.F., Beck J., Dydak U., et al. The relationship between aberrant neuronal activation in the pregenual anterior cingulate, altered glutamatergic metabolism, and anhedonia in major depression. Arch Gen Psychiatry 2009, 66:478-486.
191. Alcaro A., Panksepp J., Witczak J., Hayes D.J., Northoff G. Is subcortical-cortical midline activity in depression mediated by glutamate and GABA? A cross-species translational approach. Neurosci Biobehav Rev 2010, 34:592-605.
192. Hasenöhrl R.U., Souza-Silva M.A., Nikolaus S., Tomaz C., Brandao M.L., Schwarting R.K., et al. Substance P and its role in neural mechanisms governing learning, anxiety and functional recovery. Neuropeptides 2000, 34:272-280.
193. Kramer M.S., Cutler N., Feighner J., Shrivastava R., Carman J., Sramek J.J., et al. Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science 1998, 281:1640-1645.
194. Nikolaus S., Beu M., Wirrwar A., Vosberg H., Müller H.W., Larisch R. The contribution of small animal positron emission tomography to the neurosciences - a critical evaluation. Rev Neurosci 2004, 15:131-156.
195. Nikolaus S., Larisch R., Beu M., Antke C., Kley K., Forutan F., et al. Investigating the dopaminergic synapse in vivo. II. Molecular imaging studies in small laboratory animals. Rev Neurosci 2007, 18:473-505.
196. Nikolaus S., Larisch R., Vosberg H., Beu M., Wirrwar A., Hautzel H., et al. In vivo imaging neurotransmitter function in the rat 6-hydroxydopamine model and the relevance of findings for human Parkinson's disease. Nuklearmedizin 2011, 50:155-166.
197. Nikolaus S., Beu M., Wirrwar A., Antke C., Müller H.W. In vivo snapshots of the dopaminergic synapse in small animals. Mol Psychiatry 2005, 10:516-518.
198. Nikolaus S., Larisch R., Vosberg H., Beu M., Wirrwar A., Kley K., et al. Pharmacological challenge and synaptic response - assessing dopaminergic function in the rat striatum with small animal SPECT and PET. Rev Neurosci 2011, 22:625-645.
199. Pryce C.R., Azzinnari D., Spinelli S., Seifritz E., Tegethoff M., Meinlschmidt G. Helplessness: a systematic translational review of theory and evidence for its relevance to understanding and treating depression. Pharmacol Ther 2011, 132:242-267.
200. Schulz D., Vaska P. Integrating PET with behavioral neuroscience using RatCAP tomography. Rev Neurosci 2011, 22:647-655.